|
gptkb:Windows_Messenger
|
online status indicators
|
|
gptkb:Lotemax_eye_drops
|
post-operative inflammation
|
|
gptkb:Gunn-Peterson_trough
|
neutral hydrogen in the universe
|
|
gptkb:TTI-621
|
gptkb:Oncology
|
|
gptkb:We_Mo_Switch
|
gptkb:LED
|
|
gptkb:FACHE
|
professional achievement
|
|
gptkb:Dupilumab
|
eosinophilic esophagitis
|
|
gptkb:Fluconazole
|
esophageal candidiasis
|
|
gptkb:nizatidine
|
treatment of Zollinger-Ellison syndrome
|
|
gptkb:SDG_10
|
10.7.1
|
|
gptkb:tobramycin
|
serious infections caused by susceptible bacteria
|
|
gptkb:Am_Bisome
|
aspergillosis
|
|
gptkb:carfilzomib
|
gptkb:refractory_multiple_myeloma
|
|
gptkb:Rebetol
|
chronic hepatitis C
|
|
gptkb:Berinert
|
acute treatment of angioedema attacks
|
|
gptkb:Calquence
|
relapsed or refractory chronic lymphocytic leukemia
|
|
gptkb:SDG_16
|
Number of legal frameworks in place to promote and protect human rights
|
|
gptkb:BREEAM_Pass
|
satisfactory performance
|
|
gptkb:Sulfamethoxazole
|
urinary tract infections
|
|
gptkb:mepolizumab
|
eosinophilic asthma
|